Results 81 to 90 of about 2,398,894 (298)

Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma

, 2010
Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial ...
Rebecca L. Stone (214799), Ju-Won Roh (14904557), Hee-Dong Han (14902776), Nicholas B. Jennings (14904554), Hye-Sun Kim (50212), Alpa M. Nick (14888571), John Gooya (14982833), Jeong-Won Lee (770820), Mian M.K. Shahzad (14902779), Lingegowda S. Mangala (14888565), Sun Joo Lee (4060375), Shenlan Mao (1504684), Anil K. Sood (149701), Robert L. Coleman (14667236), Eun Ji Nam (1447849), Dowdy Jackson (508976)   +15 more
core   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

AI-driven innovation in antibody-drug conjugate design

Frontiers in Drug Discovery
Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to antigen-expressing carcinoma cells.
Heather A. Noriega, Xiang Simon Wang
doaj   +1 more source

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma [PDF]

, 2016
Patients with metastatic, platinum-resistant urothelial carcinoma (PRUC) have no Food and Drug Administration–approved therapies. The response rates to second-line chemotherapy have generally been < 20%, with a median overall survival of < 1 year.
Hajdenberg, Julio, Goldenberg, David M., Nanus, David M., Sharkey, Robert M., Tagawa, Scott T., Ocean, Allyson J., Hodes, Gillian, Faltas, Bishoy, Govindan, Serengulam V., Wilhelm, Francois   +9 more
core   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Targeted drug conjugates in cancer therapy: Challenges and opportunities

Pharmaceutical Science Advances
Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies.
Geng Jia, Yuqi Jiang, Xiaoyang Li
doaj   +1 more source

Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: A longitudinal household study [PDF]

, 2005
Background. Natural immunity to Streptococcus pneumoniae is thought to be induced by exposure to S. pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S.
Hussain, M, Virta, C, Soininen, A, Kayhty, H, Miller, E, Ashton, L, Edmunds, J, Gay, N, Goldblatt, D, Andrews, N, George, R, Pebody, R, Melegaro, A   +12 more
core  

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

, 2023
Deamidation, a common post-translational modification, may impact multiple physiochemical properties of a therapeutic protein. MEDI7247, a pyrrolobenzodiazepine (PBD) antibody–drug conjugate (ADC), contains a unique deamidation site, N102, located ...
Kathryn Ball, Dengfeng Liu, Robert J. Kubiak, Yue Huang, Jiaqi Yuan, Niluka de Mel, Lorin K. Roskos, Anton I. Rosenbaum, Meina Liang, Ruipeng Mu, Mingyan Cao, G. Patrick Hussmann   +11 more
core   +1 more source